Sysmex (OTCMKTS:SSMXY) Releases FY 2024 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 0.590-0.590 for the period. The company issued revenue guidance of $3.4 billion-$3.4 billion.

Sysmex Price Performance

SSMXY traded up $0.88 during trading on Friday, hitting $19.71. The company’s stock had a trading volume of 39,701 shares, compared to its average volume of 52,427. The company has a current ratio of 3.23, a quick ratio of 2.40 and a debt-to-equity ratio of 0.11. Sysmex has a twelve month low of $14.38 and a twelve month high of $29.78. The business’s fifty day simple moving average is $19.22 and its 200 day simple moving average is $17.60. The firm has a market capitalization of $12.40 billion, a price-to-earnings ratio of 37.16 and a beta of 0.84.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.11 earnings per share (EPS) for the quarter. The firm had revenue of $718.13 million during the quarter. On average, equities research analysts forecast that Sysmex will post 0.57 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.